目的 探討唑來膦酸致低鈣血癥的發(fā)生特點和規(guī)律，為臨床防治和安全用藥提供參考。方法 檢索PubMed、中國知網、萬方和維普等數據庫從建庫至2022年10月中涉及唑來膦酸致低鈣血癥的個案報告，對文獻進行統(tǒng)計分析。結果 共納入文獻28篇，患者35例，其中男16例，女19例，平均年齡（57.75±19.02）歲；低鈣血癥發(fā)生時間從1～30d不等，30例（90.91%）在2周內發(fā)生；16例（59.26%）患者25-羥基維生素D3水平降低，提示維生素D缺乏；27例經治療2d～5個月鈣水平恢復正常。結論 唑來膦酸可導致嚴重持久的癥狀性低鈣血癥，要重點關注高風險人群，用藥后監(jiān)測電解質變化，警惕低鈣血癥發(fā)生。

Objective To investigate the characteristics and regularity of hypocalcemia induced by zoledronic acid, so as to provide references for clinical prevention, treatment and safe drug use. Methods The case reports related to hypocalcemia induced by zoledronic acid were retrieved from PubMed, CNKI, Wanfang, and VIP databases from the establishment of the database to October 2022, and the literatures were statistically analyzed. Results A total of 28 literatures were retrieved, including 35 patients. There were 16 males and 19 females, with an average age of (57.75 ±19.02) years. The occurrence time of hypocalcemia ranged from 1 to 30 d, and 30 cases (90.91%) occurred within 2 weeks. The level of 25-OHD3 decreased in 16 cases (59.26%), suggesting vitamin D deficiency. Calcium levels of 27 patients returned to normal after 2 d to 5 months of treatment.Conclusion Zoledronic acid can cause persistent hypocalcemia with severe clinical symptoms. It is important to pay attention to high-risk groups before medication, and monitor electrolyte changes after medication to guard against hypocalcemia.

R982